Testosterone Replacement Therapy: What Two Decades of Research Reveals

The Evidence Landscape

Testosterone replacement therapy stands on remarkably solid research foundations compared to many hormonal interventions. The evidence base includes more than 50 randomised controlled trials, several large-scale observational studies following thousands of men for multiple years, and systematic reviews examining specific outcomes.

The most comprehensive data comes from the Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled studies involving 790 men aged 65 and older. These studies, published between 2016 and 2017, examined sexual function, physical performance, and vitality outcomes over 12 months. Additional landmark research includes the TRAVERSE trial, which followed over 5,000 men for an average of 33 months specifically to examine cardiovascular safety.

Systematic reviews have consistently pooled data from multiple studies, with Cochrane reviews examining both benefits and harms. The research quality varies, but the strongest studies employ proper randomisation, placebo controls, and standardised outcome measures.

What the Research Demonstrates

The evidence for TRT's effectiveness in men with confirmed testosterone deficiency is compelling. Meta-analyses consistently show significant improvements in sexual desire, erectile function, and overall sexual satisfaction. Effect sizes are typically moderate to large, with number-needed-to-treat values ranging from 4-7 for sexual benefits.

Mood and quality of life outcomes show clear benefits in multiple trials. The TTrials found significant improvements in mood and depressive symptoms using validated questionnaires. Energy levels and vitality scores improve consistently across studies, though the magnitude varies between younger and older populations.

Physical outcomes present a more nuanced picture. Lean body mass increases reliably, with typical gains of 1-2 kilograms over 6-12 months. Bone density improvements are well-documented, particularly at the spine and hip. However, functional strength gains are modest and inconsistent across trials.

Cardiovascular effects remain the most scrutinised aspect. The TRAVERSE trial found no increased risk of major cardiovascular events compared to placebo. However, earlier observational studies suggested both protective and harmful cardiovascular associations, creating ongoing debate about patient selection and monitoring.

Research Limitations and Gaps

Several significant limitations constrain our understanding of TRT's long-term profile. Most randomised trials follow participants for only 6-24 months, insufficient to capture long-term benefits or risks. The longest controlled study extended to three years, but involved only 274 participants.

Study populations are notably homogeneous. Most trials recruited predominantly white, older men with clear-cut hypogonadism. Evidence for younger men, ethnic minorities, and those with borderline testosterone levels remains limited. This restricts generalisability to real-world patient populations.

Treatment protocols vary significantly between studies. Some use testosterone gels, others intramuscular injections, and dosing strategies differ markedly. This heterogeneity makes it difficult to determine optimal treatment approaches for individual patients.

Prostate safety data, whilst reassuring in short-term studies, lacks the extended follow-up necessary to definitively rule out long-term risks. Current studies typically exclude men with elevated PSA levels, potentially missing important safety signals.

Evidence-Based vs. Uncertain Territory

The evidence strongly supports TRT for men with documented testosterone deficiency and associated symptoms. Sexual function improvements are well-established, with consistent effect sizes across multiple populations. Mood benefits and quality of life improvements have robust support from controlled trials.

Cardiovascular safety appears reassuring in carefully selected patients, based on current evidence. The TRAVERSE trial provides the strongest data to date, though questions remain about applicability to younger men or those with pre-existing cardiovascular disease.

What remains uncertain is TRT's role in age-related testosterone decline without clear deficiency. Evidence for men with testosterone levels in the lower-normal range (12-15 nmol/L) is limited and inconsistent. Performance enhancement benefits in eugonadal men lack supporting evidence.

Optimal treatment duration and monitoring protocols require further research. Current guidelines recommend annual reviews, but evidence-based discontinuation criteria are lacking.

Future Research Priorities

Several critical research questions demand attention. Long-term safety studies extending beyond five years are essential, particularly examining prostate and cardiovascular outcomes in diverse populations. Current trials are launching to address these gaps, but results won't emerge for several years.

Optimal patient selection criteria need refinement. Research should identify which symptoms predict treatment response and establish clearer testosterone thresholds for intervention. Biomarker studies examining free testosterone, sex hormone-binding globulin, and tissue sensitivity markers may improve treatment precision.

Comparative effectiveness research between delivery methods is surprisingly limited. Studies directly comparing gels, injections, and pellets using standardised outcomes would inform clinical decision-making.

Finally, research into treatment personalisation based on genetic factors, age, and comorbidities could revolutionise TRT prescribing. Current practice relies heavily on empirical dose adjustments rather than predictive models.